|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 297.08 DKK | -0.64% |
|
-3.00% | -52.28% |
| 09:26am | Sources: Novo Nordisk Group Holding reduces stake in Evotec | DP |
| 12-08 | Health Care Down Amid Intensified Obesity-Drug Competition - Health Care Roundup | DJ |
Business description: Novo Nordisk A/S
- diabetes and obesity treatment products (93.6%);
- rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).
Number of employees: 78,554
Sales by Activity: Novo Nordisk A/S
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Diabetes and Obesity Care | 108B | 122B | 156B | 215B | 272B |
Rare Disease | 18.93B | 19.2B | 20.54B | 17.16B | 18.64B |
Geographical breakdown of sales: Novo Nordisk A/S
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
United States of America (USA) | 57.82B | 63.01B | 84.66B | 128B | 167B |
EMEA | 34.3B | 37.71B | 44.24B | 50.87B | 60.4B |
Rest of the World | 17.45B | 19.81B | 25.4B | 28.08B | 33.33B |
Region China | 14.08B | 16.02B | 16.21B | 16.69B | 18.5B |
North America (Excl. US) | 3.29B | 4.25B | 6.45B | 9.1B | 10.77B |
Executive Committee: Novo Nordisk A/S
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 06/08/2025 | |
| Director of Finance/CFO | 54 | 14/02/2018 | |
Martin Lange
CTO | Chief Tech/Sci/R&D Officer | 55 | 06/08/2025 |
| Corporate Officer/Principal | 59 | - | |
Tania Sabroe
HRO | Human Resources Officer | 48 | 31/12/2021 |
Composition of the Board of Directors: Novo Nordisk A/S
| Director | Title | Age | Since |
|---|---|---|---|
Kasim Kutay
BRD | Director/Board Member | 60 | 22/03/2017 |
| Director/Board Member | 50 | 21/03/2018 | |
Thomas Rantzau
BRD | Director/Board Member | 53 | 21/03/2018 |
| Director/Board Member | 60 | 23/03/2022 | |
| Director/Board Member | 59 | 28/02/2014 | |
| Chairman | 71 | 13/11/2025 | |
Cees de Jong
BRD | Director/Board Member | 64 | 13/11/2025 |
| Director/Board Member | 52 | 13/11/2025 | |
Stephan Engels
BRD | Director/Board Member | 63 | 13/11/2025 |
Holdings: Novo Nordisk A/S
| Name | Equities | % | Valuation |
|---|---|---|---|
NOVO NORDISK A/S 0.77% | 25,947,151 | 0.77% | 1,278,105,283 $ |
NNIT A/S 17.5% | 4,375,000 | 17.5% | 32,971,400 $ |
INNATE PHARMA 9.65% | 8,895,649 | 9.65% | 18,046,069 $ |
Company details: Novo Nordisk A/S
Group companies: Novo Nordisk A/S
| Name | Category and Sector |
|---|---|
Novo Nordisk Service Centre (India) Pvt Ltd.
 Novo Nordisk Service Centre (India) Pvt Ltd. Part of BNP Paribas SA, Novo Nordisk Service Centre (India) Pvt Ltd. is a company based in Bangalore, India. The company was founded in 2011. | |
Novo Nordisk Service Centre (India) Pvt Ltd.
Novo Nordisk Service Centre (India) Pvt Ltd. Part of BNP Paribas SA, Novo Nordisk Service Centre (India) Pvt Ltd. is a company based in Bangalore, India. The company was founded in 2011. | |
NNE A/S
 NNE A/S Engineering & ConstructionIndustrial Services Supplies systems, consultancy and engineering services |
Engineering & Construction
|
NNE A/S
NNE A/S Engineering & ConstructionIndustrial Services Supplies systems, consultancy and engineering services |
Engineering & Construction
|
Novo Nordisk Health Care AG
 Novo Nordisk Health Care AG Develops, manufactures, markets and distributes pharmaceutical products |
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.80% | -2.93% | -61.90% | -35.33% | 207B | |
| -1.26% | -5.70% | +20.67% | +168.32% | 893B | |
| -0.15% | -1.81% | +35.03% | +13.78% | 486B | |
| -1.31% | -0.88% | +26.64% | +34.42% | 394B | |
| +0.14% | +1.76% | +23.95% | +4.66% | 336B | |
| +1.27% | -0.28% | +28.59% | +21.21% | 280B | |
| +0.28% | +0.75% | +19.71% | +25.18% | 253B | |
| -0.79% | -2.85% | -4.04% | -10.75% | 246B | |
| -2.63% | -4.82% | +17.85% | +12.49% | 173B | |
| -0.02% | -2.53% | +31.54% | +35.45% | 150B | |
| Average | -0.51% | -2.03% | +13.81% | +26.94% | 341.87B | |
| Weighted average by Cap. | -0.61% | -2.41% | +17.87% | +53.25% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVO B Stock
- Company Novo Nordisk A/S
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition